血小板减少症靶向药——孟加拉艾曲波帕(Revolade)注意事项

印度代购提示您，本品艾曲波帕可能引起肝毒性。观察到血清中转氨酶水平和胆红素增加。治疗开始前和治疗期间常规必须测定肝化学。肝功能受损患者给药时应小心谨慎。艾曲波帕是促血小板生成素受体激动剂和TPO-受体激动剂增加骨髓内网状纤维沉积的发展或进展的风险。为骨髓纤维化征象监查外周血。中断可能导致比治疗前存在血小板减少。中断后每周监查全血细胞计数(CBC)，血小板计数至少4周。艾曲波帕剂量过量可能增高血小板计数至一个产生血栓形成/血栓栓塞并发症水平。

Attripopa may cause hepatotoxicity. Increased serum transaminase levels and bilirubin were observed. Liver chemistry must be measured routinely before and during treatment. Patients with impaired liver function should be treated with caution. Altribopa is a thromboplastin receptor agonist and a TPO-receptor agonist that increases the risk of development or progression of intramedullary reticular fiber deposition. Peripheral blood was monitored for signs of myelofibrosis. Interruption may result in the presence of thrombocytopenia before treatment. Complete blood count (CBC) and platelet count were monitored weekly for at least 4 weeks after interruption. An overdose of atripopal may increase platelet count to a level that produces thrombotic/thromboembolic complications.

印度代购提示您，本品艾曲波帕可能增高血液病恶性病的风险，特别是在骨髓增生异常综合征患者。用艾曲波帕治疗调整剂量期时每周监查CBC，包括血小板计数和外周血涂片，然后确定每月稳定剂量。

Altripopa may increase the risk of hematologic malignancy, especially in patients with myelodysplastic syndrome. CBC was monitored weekly, including platelet count and peripheral blood smears, during the dose adjustment period with attripopa, and the monthly stable dose was determined.